Small molecules as friends and foes of the immune system

Future Medicinal Chemistry

Volumn 1, Issue 9, 2009, Pages 1583-1591

  Kadow, Stephanie ^a   Jux, Bettina ^a   Chmill, Stefanie ^a   Esser, Charlotte ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON; B LYMPHOCYTE RECEPTOR; HAPTEN; IMMUNOGLOBULIN; NATURAL KILLER CELL RECEPTOR; SCAVENGER RECEPTOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; XENOBIOTIC AGENT;

ALLERGY; AUTOIMMUNITY; CHEMICAL ENVIRONMENT; ENZYME METABOLISM; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; LANGERHANS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

IMMUNE SYSTEM; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; XENOBIOTICS;

EID: 77953460148     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.125     Document Type: Short Survey

References (71)

1. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol. Today 19(3), 133-141 (1998).
2. Landsteiner K, Jacobs J. Studies on the sensitiziation of animals with simple chemical compounds. J. Exp. Med. 61, 643-656 (1935).
3. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur. J. Immunol. 27(6), 1303-1307 (1997).
4. Kalish RS, Johnson KL. Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J. Immunol. 145(11), 3706-3713 (1990).
5. Takahashi K, Kropshofer H, Vogt AB, Gleichmann E, Griem P. Drug-induced inhibition of insulin recognition by T-cells. the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. Mol. Immunol. 35(17), 1081-1087 (1998).
6. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456), 15-19 (2004).
7. Pichler WJ, Beeler A, Keller M et al. Pharmacological interaction of drugs with immune receptors. The p-i concept. Allergol. Int. 55(1), 17-25 (2006).
8. Esser C. Immunotoxicology. In: Comprehensive Medicinal Chemistry II. Taylor JB, Triggle DJ (Eds). Elsevier, UK, 215-229 (2007).
9. Recio L, Bauer A, Faiola B. Use of genetically modified mouse models to assess pathways of benzene-induced bone marrow cytotoxicity and genotoxicity. Chem. Biol. Interact. 153-164 (2005).
10. Cardenas ME, Sanfridson A, Cutler NS, Heitman J. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16(10), 427-433 (1998).
11. Matsuda S, Koyasu S. Regulation of MAPK signaling pathways through immunophilin - ligand complex. Curr. Top. Med. Chem. 3(12), 1358-1367 (2003).
12. Martinez-Martinez S, Redondo JM. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem. 11(8), 997-1007 (2004).
13. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9(5), 324-337 (2009).
14. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin. Investig. Drugs 17(7), 1051-1065 (2008).
15. Novak N, Yu CF, Bieber T, Allam JP. Toll-like receptor 7 agonists and skin. Drug News Perspect. 21(3), 158-165 (2008).
16. Zhu LX, Sharma S, Gardner B et al. IL-10 mediates s1 receptor-dependent suppression of antitumor immunity. J. Immunol. 170(7), 3585-3591 (2003).
17. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J. Neuroimmune Pharmacol. 1(3), 280-295 (2006).
18. Strober W. Vitamin A rewrites the ABCs of oral tolerance. Mucosal. Immunol. 1(2), 92-95 (2008).
19. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30(5), 626-635 (2009).
20. He YW. Orphan nuclear receptors in T lymphocyte development. J. Leukoc. Biol. 72(3), 440-446 (2002).
21. Von Schmiedeberg S, Fritsche E, Rönnau AC et al. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv. Exp. Med. Biol. 455, 147-152 (1999).
22. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin. Pharmacokinet. 6(2), 118-134 (1981).
23. Richter-Hintz D, Thier R, Steinwachs S et al. Allelic variants of drug metabolizing enzymes as risk factors in psoriasis. J. Invest. Dermatol. 120(5), 765-770 (2003).
24. Kramer U, Esser C. Cigarette smoking, metabolic gene polymorphism and psoriasis. J. Invest. Dermatol. 126(3), 693-694 (2006).
25. Klareskog L, Wedren S, Alfredsson L. On the origins of complex immune-mediated disease. the example of rheumatoid arthritis. J. Mol. Med. 87(4), 357-362 (2009).
26. Ju C, Pohl LR. Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions. Toxicology 209(2), 109-112 (2005).
27. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202 (2005).
28. Schecter A, Birnbaum L, Ryan JJ, Constable JD. Dioxins: an overview. Environ. Res. 101(3), 419-428 (2006).
29. Lindell M, Lang M, Lennernas H. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. 28(1), 41-48 (2003).
30. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 61(5), 541-558 (2009).
31. Saeki M, Saito Y, Nagano M, Teshima R, Ozawa S, Sawada J. mRNA expression of multiple cytochrome p450 isozymes in four types of cultured skin cells. Int. Arch. Allergy Immunol. 127(4), 333-336 (2002).
32. Swanson HI. Cytochrome P450 expression in human keratinocytes. an aryl hydrocarbon receptor perspective. Chem. Biol. Interact. 149(2-3), 69-79 (2004).
33. Bergstrom MA, Ott H, Carlsson A et al. A skin-like cytochrome P450 cocktail activates prohaptens to contact allergenic metabolites. J. Invest. Dermatol. 127(5), 1145-1153 (2007).
34. Schrenk D. Impact of dioxin-type induction of drug-metabolizing enzymes on the metabolism of endo- and xenobiotics. Biochem. Pharmacol. 55(8), 1155-1162 (1998).
35. Beischlag TV, Luis MJ, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 18(3), 207-250 (2008).
36. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43, 309-334 (2003).
37. Ma Q, Kinneer K, Bi Y, Chan JY, Kan YW. Induction of murine NAD(P)H.quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzop- dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction. Biochem. J. 377(1), 205-213 (2004).
38. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschlager M, Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J. Immunol. 183(1), 66-74 (2009).
39. Wang L, Bursch LS, Kissenpfennig A, Malissen B, Jameson SC, Hogquist KA. Langerin expressing cells promote skin immune responses under defined conditions. J. Immunol. 180(7), 4722-4727 (2008).
40. Jux B, Kadow S, Esser C. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J. Immunol. 182(11), 6709-6717 (2009).
41. Sanderson JP, Naisbitt DJ, Park BK. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 8(1), E55-E64 (2006).
42. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor and immunity. Trends Immunol. 9, 447-454 (2009).
43. Esser C. The immune system of Ahr null mutant mouse strains - not a simple mirror of xenobiotic receptor over-activation. Biochem. Pharmacol. 77, 597-607 (2009).
44. McMillan BJ, Bradfield CA. The aryl hydrocarbon receptor sans xenobiotics. endogenous function in genetic model systems. Mol. Pharmacol. 72(3), 487-498 (2007).
45. Bock KW, Kohle C. Ah receptor: dioxinmediated toxic responses as hints to deregulated physiologic functions. Biochem. Pharmacol. 72(4), 393-404 (2006).
46. Veldhoen M, Hirota K, Westendorf AM et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191), 106-109 (2008).
47. Stockinger B. Beyond toxicity: aryl hydrocarbon receptor-mediated functions in the immune system. J. Biol. 8(7), 61 (2009).
48. Von Bubnoff D, Bausinger H, Matz H et al. Human epidermal Langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. J. Invest. Dermatol. 123(2), 298-304 (2004).
49. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 113(11), 2394-2401 (2009).
50. Funatake CJ, Marshall NB, Steppan LB, Mourich DV, Kerkvliet NI. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo- p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J. Immunol. 175(7), 4184-4188 (2005).
51. Vorderstrasse BA, Dearstyne EA, Kerkvliet NI. Influence of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the antigen-presenting activity of dendritic cells. Toxicol. Sci. 72(1), 103-112 (2003).
52. Kobayashi S, Okamoto H, Iwamoto T et al. A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritis. Rheumatology 47(9), 1317-1322 (2008).
53. Quintana FJ, Basso AS, Iglesias AH et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191), 65-71 (2008).
54. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10, 857-863 (2009).
55. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 21(2), 241-254 (2004).
56. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 373(9664), 659-672 (2009).
57. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol. Lett. 112-113, 421-432 (2000).
58. Fritsche E, Schafer C, Calles C et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc. Natl Acad. Sci. USA 104(21), 8851-8856 (2007).
59. Hauben E, Gregori S, Draghici E et al. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112(4), 1214-1222 (2008).
60. Negishi T, Kato Y, Ooneda O et al. Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J. Immunol. 175(11), 7348-7356 (2005).
61. Lawrence BP, Denison MS, Novak H et al. Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood 112(4), 1158-1165 (2008).
62. Flaveny CA, Murray IA, Chiaro CR, Perdew GH. Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol. Pharmacol. 75(6), 1412-1420 (2009).
63. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol. Life Sci. 63(1), 60-72 (2006).
64. Shuster EA. Hormonal influences in multiple sclerosis. Curr. Top. Microbiol. Immunol. 318, 267-311 (2008).
65. Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J. Exp. Med. 195(2), 171-179 (2002).
66. Yao C, Sakata D, Esaki Y et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat. Med. 15(6), 633-640 (2009).
67. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendriticcell maturation. Blood 106(7), 2375-2381 (2005).
68. Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb. Exp. Pharmacol. 188, 251-273 (2009).
69. Costa-Iborra B, Elorza A, Olazabal IM et al. Macrophage oxygen sensing modulates antigen presentation and phagocytic functions involving IFN-g production through the HIF-1 a transcription factor. J. Immunol. 182(5), 3155-3164 (2009).
70. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. 58(Suppl. 1), I107-I113 (1999).
71. Kerkvliet NI. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int. Immunopharmacol. 2(2-3), 277-291 (2002).